OTSUKA PHARMACEUTICAL DEVELOPMENT & COMMERCIALIZATION, INC.
Trial to Evaluate the Long-term Efficacy of Oral Aripiprazole in the Treatment of Pediatric Participants With Tourette's Disorder
- First Posted Date
- 2018-09-07
- Last Posted Date
- 2021-03-09
- Target Recruit Count
- 36
- Registration Number
- NCT03661983
- Locations
- 🇺🇸
Reliable Clinical Research, Hialeah, Florida, United States
🇺🇸Pediatric and Adolescent Neurodevelopment Associates, Atlanta, Georgia, United States
🇺🇸Alivation, Lincoln, Nebraska, United States
A Trial to Measure the Difference in All-cause Hospitalizations for Participants Who Are Using Abilify MyCite Versus Virtual Matched Controls in Adults With Schizophrenia, Bipolar 1 Disorder, and Major Depressive Disorder
- First Posted Date
- 2018-08-22
- Last Posted Date
- 2019-11-08
- Target Recruit Count
- 2
- Registration Number
- NCT03643159
- Locations
- 🇺🇸
Psychiatric Addiction Curative/PACT Atlanta LLC, Decatur, Georgia, United States
🇺🇸Kolade Research Institute, Las Vegas, Nevada, United States
🇺🇸Georgia Psychiatry and Sleep, Smyrna, Georgia, United States
A Trial to Evaluate the Efficacy, Safety, and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder
- Conditions
- Interventions
- First Posted Date
- 2018-07-30
- Last Posted Date
- 2021-10-18
- Target Recruit Count
- 590
- Registration Number
- NCT03605836
- Locations
- 🇺🇸
For additional information regarding sites, contact 844-687-8522, Orlando, Florida, United States
A Trial Evaluating the Long-term Safety and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder
- Conditions
- Interventions
- First Posted Date
- 2018-07-30
- Last Posted Date
- 2024-10-01
- Target Recruit Count
- 662
- Registration Number
- NCT03605849
- Locations
- 🇺🇸
For additional information regarding sites, contact 844-687-8522, Culver City, California, United States
A Trial Evaluating the Efficacy, Safety, & Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder
- Conditions
- Interventions
- First Posted Date
- 2018-07-30
- Last Posted Date
- 2022-03-15
- Target Recruit Count
- 604
- Registration Number
- NCT03605680
- Locations
- 🇺🇸
For additional information regarding sites, contact 844-687-8522, New York, New York, United States
A 12-week Extension Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type
- First Posted Date
- 2018-07-20
- Last Posted Date
- 2023-11-14
- Target Recruit Count
- 259
- Registration Number
- NCT03594123
- Locations
- 🇺🇸
For additional information regarding sites, contact 844-687-8522, Miami, Florida, United States
A Trial to Explore Acceptance and Performance of Using a Digital Medicine System With Healthcare Professionals and Adults With Schizophrenia, Schizoaffective Disorder, or First Episode Psychosis on an Oral Atypical Antipsychotic
- First Posted Date
- 2018-06-26
- Last Posted Date
- 2020-07-16
- Target Recruit Count
- 44
- Registration Number
- NCT03568500
- Locations
- 🇬🇧
Clinical Trial Site, Southampton, United Kingdom
A Trial to Evaluate the Safety, Efficacy, and Tolerability of Brexpiprazole in Treating Agitation Associated With Dementia of the Alzheimer's Type
- Conditions
- Interventions
- First Posted Date
- 2018-06-07
- Last Posted Date
- 2023-09-18
- Target Recruit Count
- 345
- Registration Number
- NCT03548584
- Locations
- 🇺🇸
For additional information regarding sites, contact 844-687-8522, Los Angeles, California, United States
A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder
- Conditions
- Interventions
- First Posted Date
- 2018-05-29
- Last Posted Date
- 2023-10-12
- Target Recruit Count
- 1149
- Registration Number
- NCT03538691
- Locations
- 🇺🇸
For additional information regarding sites, contact 844-687-8522, Los Angeles, California, United States
Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Intermittent Explosive Disorder
- First Posted Date
- 2018-02-05
- Last Posted Date
- 2022-05-24
- Target Recruit Count
- 10
- Registration Number
- NCT03420222
- Locations
- 🇺🇸
Sarkis Clinical Trials, Gainesville, Florida, United States
🇺🇸Atlanta Center for Medical Research, Atlanta, Georgia, United States
🇺🇸University of Chicago Medical Center Clinical Trial Site 2, Chicago, Illinois, United States